Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment.

Danielle Groat Karlyn A Martin Rachel P Rosovsky Kristen M Sanfilippo Manila Gaddh Lisa Baumann KreuzigerM Elaine EysterScott C Wollernull null

Published in: Research and practice in thrombosis and haemostasis (2022)

Most clinicians elect to dose-reduce DOACs for extended-phase anticoagulation. The likelihood of a clinician to dose reduce increases with volume of patients treated. Clinician prescribing patterns cluster around VTE risk factors as well as reescalation during high-risk periods.

Keyphrases

venous thromboembolism
direct oral anticoagulants
primary care
risk factors
atrial fibrillation
emergency department
healthcare
combination therapy
replacement therapy
electronic health record